Objective?To verify the performance of soluble growth stimulating express gene 2 (sST2) protein detection based on the magnetic microparticle chemiluminescence method, and evaluate its stability and reliability.?Methods?The serum samples from patients and healthy persons and quality control materials provided by the manufacturer were detected by the kit based on the magnetic microparticle chemiluminescence method, and its performance was evaluated.?Results?When the samples were detected one day at a time for 5 days, the coefficients of variation (CVs) of serum samples with low and high sST2 levels were 2.2% and 2.3%, respectively, and those of quality control materials were 1.7% and 1.5%, respectively. When the samples were detected 20 times repeatedly, the?CVs?of serum samples with low and high sST2 levels were 1.07% and 1.41%, respectively, and those of quality control materials were 0.98% and 1.23%, respectively. When serum sST2 levels were in the range of 1.00-300.00 ng/mL, the correlation coefficient (r) was 0.999 9 and 0.999 8. When the sST2 levels in quality control materials were in the range of 6.40-200.00 ng/mL, the?r?was beyond 0.999 9. The lowest detection limit of the kit was 0.028 ng/mL. When serum samples were diluted to 40 folds, the detection results of the kit were still accepted. The levels of serum sST2 from 40 healthy persons were in the reference interval. The positive and negative coincidence rates were 96.88% and 96.55%, respectively, between the kit and reference method. The relative deviations of serum samples with low and high sST2 levels were -15.3% and -14.6% for storing 3 days at room temperature, -0.44% and 0.39% for storing 7 days at 2-8 ℃, and -2.08% and -0.72% for storing 7 days at -20 ℃, respectively. There was no obvious interference effect on the detection of serum sST2 levels when the concentrations of serum bilirubin, hemoglobin and fat emulsion were less than 1 mmol/L, 10 g/L and 20 g/L, respectively.?Conclusion?All of the precision, repeatability, linear range, lowest detection limit, clinical reportable range, reference interval validation, and the results of clinical sample comparison test, sample stability test and interference test of the detection kit based on the magnetic microparticle chemiluminescence method meet the requirements of clinical application, which can be applied in the clinical laboratory.